It is known that manipulation of checkpoint cell-surface signaling molecules can exert potent anticancer effects. Immune checkpoint therapy has recently reached important clinical advances [8, 9]. Indeed, it has been reported that cancer patients treated with anti-CTLA-4 (Ipilimumab) or anti-PD-1 (Nivolumab or Pembrolizumab) blocking antibodies showed an increase of the antitumor T-cell response and a higher rate of disease free survival [10–13]. Additionally, antibodies blocking PD-L1 were shown to be superior to Ipilimumab by having a better safety profile. Therapies combining both Ipilimumab and Nivolumab in patients with metastatic melanoma, have shown significant increase of the progression-free survival rate. However, this combination was also associated with substantial immune related toxicities [12, 14–17].